Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × azeliragon × Clear all
NCT05789589 2026-03-04

ADORATION

Baptist Health South Florida

Phase 1/2 Recruiting
46 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting
48 enrolled
Breast

Cancer Related Cognitive Decline

NCT05766748 2024-06-14

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Cantex Pharmaceuticals

Phase 1/2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡